Please assess the completion status of the following clinical trial:

Trial Title: Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed or refractory DLBCL~* More than 1 line of prior chemotherapy~Exclusion Criteria:~* Currently receiving anticancer therapy or investigational agents~* Major surgery within last 4 weeks~* Known leptomeningeal or brain metastases~* Known HIV infection~* Uncontrolled fungal, bacterial, viral or other infection~* History of another malignancy (except for non-melanoma skin cancer or in situ cervical or breast cancer) unless disease free for at least 3 years~* Hepatitis B or C positive~* GI disease~* Pregnant or breastfeeding~* Prior treatment with an HDAC inhibitor including valproic acid

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Panobinostat/Rituximab (Type: EXPERIMENTAL): single-arm, open-label; Panobinostat with Rituximab: Panobinostat 40 mg orally 3 x weekly Rituximab 375 mg/m\^2 IV days 1,8,15,and 22 of cycle 1, and then on day 1 of subsequent cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).